cystic fibrosis

Treating the root cause of cystic fibrosis, rather than just the symptoms, may be an ideal approach to improving patient outcomes for people with the disease. Thanks to a new study conducted by scientists at Howard Hughes Medical Institute and University of Illinois at Urbana-Champaign, a treatment strategy based on this concept may…

The pathogen Pseudomonas aeruginosa is the most common infectious agent that affects cystic fibrosis patients and leads to chronic pulmonary infection and progressive lung damage. Researchers have been hard at work developing a vaccine against Pseudomonas aeruginosa to administer to cystic fibrosis patients to prevent colonization and subsequent lung damage,…

The first-of-its kind Kitabis Pak, a co-packaged generic tobramycin inhalation solution and PARI LC PLUS Nebulizer indicated for cystic fibrosis, was recently named one of 2014’s 10 notable drug-device approvals. The list is currently published in this month’s issue of Drug Development & Delivery. The Kitabis…

Raptor Pharmaceutical Corp., recently announced it has reached an agreement with Tripex Pharmaceuticals over the rights to Quinsair, a first-of-its-kind inhaled fluoroquinolone indicated for chronic respiratory infections caused by Psuedomonas aeruginosa in adult cystic fibrosis patients. Quinsair was granted marketing authorization by the European Commission and Health Canada earlier this year.

Newly found workings of Pseudomonas aeruginosa may explain why certain medications are only modestly effective in patients with cystic fibrosis. A group of researchers led by Dr. Pradeep Singh and Dr. Peter Jorth at the University of Washington School of Medicine discovered that when P. aeruginosa infects cystic fibrosis patients’…

Global biotechnology company and Cystic Fibrosis therapeutic leader Vertex, together with the University of Massachusetts (UMass), recently revealed the awardees of the yearly Vertex Science Leaders Scholarship, which will fund 4 years of their education in any Science, Technology, Engineering and Math (STEM) course at any UMass campus. This scholarship is part…

The CF Foundation’s Cystic Fibrosis Research Development Program (RDP) recently expanded its network to include new CF centers in Denver and Atlanta, two cities that house the two largest CF treatment centers in the country. The new RDP in Denver, Colorado will be awarded to $2.1 million in funding, to be…

A study recently published in the journal PLoS One reported on the effectiveness of a new diagnostic tool for detecting pulmonary diseases in children, including cystic fibrosis (CF). The study was led by researchers at the Hanover Medical School in Germany and is entitled “…

In a new study entitled “Cysteamine as a future intervention in cystic fibrosis against current and emerging pathogens: a patient-based ex vivo study confirming its antimicrobial and mucoactive potential in sputum,” a team of scientists show for the first time that NovaBiotics’ therapy for Cystic Fibrosis, Cysteamine…

The Mauli Ola Foundation is crossing the country once again to support patients who suffer from cystic fibrosis (CF). The organization is hosting the East Coast Tour from Texas to New York until August 28, and this year the event is being held under the name “The Humuhumunukunukuapua’a…